Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1386268

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1386268

Leber Congenital Amaurosis Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Leber Congenital Amaurosis Trends and Forecast

The future of the global leber congenital amaurosis (LPA) market looks promising with opportunities in the hospital, specialty clinic, ambulatory surgical center, and home healthcare markets. The global leber congenital amaurosis market is expected to reach an estimated $1.26 billion by 2030 with a CAGR of 4.2% from 2024 to 2030. The major drivers for this market are growing incidence of rpe65 gene-mediated in retinal diseases, governments around the world are increasing funding for research into LCA, and rising investment from pharmaceutical companies.

A more than 150-page report is developed to help in your business decisions.

Leber Congenital Amaurosis by Segment

The study includes a forecast for the global leber congenital amaurosis by type, disease type, end use, distribution channel, and region.

Leber Congenital Amaurosis Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Therapy
  • Diagnosis

Leber Congenital Amaurosis Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Infantile Type
  • Juvenile Type
  • Others

Leber Congenital Amaurosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare
  • Others

Leber Congenital Amaurosis Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Direct Tender
  • Retail Sales

Leber Congenital Amaurosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Leber Congenital Amaurosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies leber congenital amaurosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the leber congenital amaurosis companies profiled in this report include-

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN

Leber Congenital Amaurosis Market Insights

Lucintel forecasts that therapy is expected to witness higher growth over the forecast period due to growing unmet need for effective treatments for LCA.

Within this market, hospital will remain the largest segment as it provides necessary equipment and expertise to diagnose and treat LCA.

North America will remain the largest region over the forecast period due to a well-developed healthcare infrastructure.

Features of the Global Leber Congenital Amaurosis Market

Market Size Estimates: Leber congenital amaurosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Leber congenital amaurosis market size by various segments, such as by type, disease type, end use, distribution channel, and region in terms of ($B).

Regional Analysis: Leber congenital amaurosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, disease types, end uses, distribution channels, and regions for the leber congenital amaurosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the leber congenital amaurosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the leber congenital amaurosis market size?

Answer: The global leber congenital amaurosis market is expected to reach an estimated $1.26 billion by 2030.

Q.2 What is the growth forecast for leber congenital amaurosis market?

Answer: The global leber congenital amaurosis market is expected to grow with a CAGR of 4.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the leber congenital amaurosis market?

Answer: The major drivers for this market are growing incidence of rpe65 gene-mediated in retinal diseases, governments around the world are increasing funding for research into LCA, and rising investment from pharmaceutical companies.

Q4. What are the major segments for leber congenital amaurosis market?

Answer: The future of the leber congenital amaurosis market (LCA) looks promising with opportunities in the hospital, specialty clinic, ambulatory surgical center, and home healthcare markets.

Q5. Who are the key leber congenital amaurosis market companies?

Answer: Some of the key leber congenital amaurosis companies are as follows:

  • Invitae Corporation
  • Spark Therapeutics
  • LKC Technologies
  • CENTOGENE
  • Optos
  • Metrovision
  • Blue Print Genetics Oy
  • CD Genomics
  • ProQR Therapeutics
  • OCUGEN

Q6. Which leber congenital amaurosis market segment will be the largest in future?

Answer: Lucintel forecasts that therapy is expected to witness higher growth over the forecast period due to growing unmet need for effective treatments for LCA.

Q7. In leber congenital amaurosis market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to a well-developed healthcare infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the leber congenital amaurosis market by type (therapy and diagnosis), disease type (infantile type, juvenile type , and others), end use (hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others), distribution channel (direct tender and retail sales), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Leber Congenital Amaurosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Leber Congenital Amaurosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Leber Congenital Amaurosis Market by Type
    • 3.3.1: Therapy
    • 3.3.2: Diagnosis
  • 3.4: Global Leber Congenital Amaurosis Market by Disease Type
    • 3.4.1: Infantile Type
    • 3.4.2: Juvenile Type
    • 3.4.3: Others
  • 3.5: Global Leber Congenital Amaurosis Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Specialty Clinics
    • 3.5.3: Ambulatory Surgical Centers
    • 3.5.4: Home Healthcare
    • 3.5.5: Others
  • 3.6: Global Leber Congenital Amaurosis Market by Distribution Channel
    • 3.6.1: Direct Tender
    • 3.6.2: Retail Sales

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Leber Congenital Amaurosis Market by Region
  • 4.2: North American Leber Congenital Amaurosis Market
    • 4.2.2: North American Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.3: European Leber Congenital Amaurosis Market
    • 4.3.1: European Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.3.2: European Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.4: APAC Leber Congenital Amaurosis Market
    • 4.4.1: APAC Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.4.2: APAC Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others
  • 4.5: ROW Leber Congenital Amaurosis Market
    • 4.5.1: ROW Leber Congenital Amaurosis Market by Type: Therapy and Diagnosis
    • 4.5.2: ROW Leber Congenital Amaurosis Market by End Use: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Type
    • 6.1.2: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Disease Type
    • 6.1.3: Growth Opportunities for the Global Leber Congenital Amaurosis Market by End Use
    • 6.1.4: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Distribution Channel
    • 6.1.5: Growth Opportunities for the Global Leber Congenital Amaurosis Market by Region
  • 6.2: Emerging Trends in the Global Leber Congenital Amaurosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Leber Congenital Amaurosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Leber Congenital Amaurosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Invitae Corporation
  • 7.2: Spark Therapeutics
  • 7.3: LKC Technologies
  • 7.4: CENTOGENE
  • 7.5: Optos
  • 7.6: Metrovision
  • 7.7: Blue Print Genetics Oy
  • 7.8: CD Genomics
  • 7.9: ProQR Therapeutics
  • 7.10: OCUGEN
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!